Skip to main content
Equibles
NMRA logo

NMRA · Neumora Therapeutics, Inc.

Track NMRA — free

Use NMRA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about NMRA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.60 -0.13 (-7.51%) At close · Aug 14
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“the current available cash and cash equivalents will not be sufficient to fund the Company’s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$300.63M
Shares
187.90M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.60 Open$1.69 Day$1.58–1.71 52W close$0.92–3.59 Avg vol 30d761K Short int7.6M · 4.1% float · 11.0d Short vol64% Last earningsMar 30, 2026 DataSep 2023–Aug 2026 Filing10-Q · Aug 14

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 14, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −26%
      below
      Price vs 50-day avg −1%
      below
      RSI (14) 47
      neutral
      MACD trend Positive
      52-week position 26%
      mid-range
      Momentum
      relative strength
      Very Weak
      1-month return −1%
      trailing
      6-month return −54%
      trailing
      YTD return −11%
      this year
      Relative strength −67%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $2 › 200d $2 — 200d above 50d
      Institutional flow Distributing
      -2% holders QoQ · +28 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      4.06% of float · ▼ -2.1% MoM · 11.0 days cover
      Volume signal Reversal watch
      High volume on a down day — possible exhaustion
      Institution breadth Steady
      112 holders — mid 3-yr range
      Squeeze score 69
      elevated · 0–100
      Fundamentals
      Fair
      EPS growth +5%
      Y/Y
      Free cash flow $-206.6M
      Balance sheet $68.0M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 124%
      annualized · 1-yr
      Max drawdown −75%
      past year
      ATR 7.0%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 4 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −26% Bearish
      Price vs 50-day avg
      −1% Neutral
      RSI (14)
      47 Neutral
      MACD trend
      Positive Bullish
      52-week position
      26% Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $2 › 200d $2 — 200d above 50d
      Institutional flow Distributing
      -2% holders QoQ · +28 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      4.06% of float · ▼ -2.1% MoM · 11.0 days cover
      Volume signal Reversal watch
      High volume on a down day — possible exhaustion
      Institution breadth Steady
      112 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $1 Now $2 · 26% Range high $4
      vs 200-day avg -26% vs 50-day avg -1%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      NMRA
      Neumora Therapeutics, Inc.
      this stock
      		$300.63M -10.6% — — 4.1%
      ONC
      BeOne Medicines Ltd.
      		 $513.62B +14.4% +22179.2% 789.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $128.19B +11.6% +46.2% 29.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $82.72B +4.1% +20.8% 19.9 3.3%
      ARGX
      Argenx SE
      		 $52.94B +1.2% — — 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      112
      % held
      41.8%
      Net QoQ
      +6.2M sh
      Top holder
      Siren, L.L.C.
      Held Float
      View
      Held by Funds
      Fund positions
      44
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      7.6M
      Days to cover
      11.0d
      Change
      -163.8K sh
      View
      Short Volume
      Short vol %
      64%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      6.3K
      Value
      $10.8K
      As of
      Jun 30, 2026
      View
      Off-Exchange
      Off-exchange %
      34.3%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Net income (FY)
      $-236.9M
      EPS diluted
      $-1.45
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 14, 2026
      This year
      14
      View
      Proposed Sales
      Value
      $21.1K
      Shares
      6.0K
      Filed
      Feb 17, 2026
      View
      Exempt Offerings
      Offering
      $474.4M
      Filed
      Jan 3, 2023
      View
      Earnings & Events
      Earnings Calls
      Last call
      Apr 13, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      NMRA -1.8% -0.6% -53.6% -0.6% -10.6%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -2.2% -5.1% -67.4% -4.5% -24.5%
      Key facts CIK 1885522 CUSIP 640979100 13F (30d) 114 filings 112 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)